A Study of Brenipatide in Participants With Opioid Use Disorder

Abroad (travel likely)RecruitingPHASE2

Conditions

Opioid Use Disorder

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • NoesisPharma - Phoenix - East Shea Boulevard, Phoenix, Arizona, United States

    Contact: Principal Investigator (John Prater)
  • Pillar Clinical Research- Little Rock, Little Rock, Arkansas, United States

    Contact: Principal Investigator (Leslie Smith)
  • Woodland International Research Group, Little Rock, Arkansas, United States

    Study coordinator · 501-221-8681
    Contact: Principal Investigator (George Konis)
  • Ark Clinical Research - Fountain Valley, Fountain Valley, California, United States

    Study coordinator · 714-988-2021
    Contact: Principal Investigator (Justin Yanuck)
  • Center on Substance Use and Health (CSUH), San Francisco, California, United States

    Contact: Principal Investigator (Phillip Coffin)
  • UCSF Weill Institute for Neurosciences - Substance Use Disorders Clinic - Mission Bay, San Francisco, California, United States

    Contact: Principal Investigator (Khaled Moussawi)
  • Bradenton Research Center, Inc., Bradenton, Florida, United States

    Study coordinator · 941-708-0005
    Contact: Principal Investigator (Eric Folkens)
  • K2 Medical Research - Daytona Beach, Daytona Beach, Florida, United States

    Contact: Principal Investigator (Esteban Olivera)
  • NextPhase Research Florida - Hollywood, Hollywood, Florida, United States

    Contact: Principal Investigator (Peter Ventre)
  • Accel Research Sites - Lakeland Clinical Research Unit, Lakeland, Florida, United States

    Study coordinator · 863-940-2087
    Contact: Principal Investigator (James Andersen)
  • Life Arc Research Centers - Miami, Miami, Florida, United States

    Study coordinator · 305-874-7401
    Contact: Principal Investigator (Janny Rivera)
  • Advanced Research for Health Improvement, LLC, Naples, Florida, United States

    Study coordinator · 239-230-2021
    Contact: Principal Investigator (Leonard Lado)
  • Innovative Research Institute - Port Charlotte, Port Charlotte, Florida, United States

    Study coordinator · 941-505-2100
    Contact: Principal Investigator (Joseph Ravid)
  • Better Years Ahead Medical Center, Tampa, Florida, United States

    Study coordinator · 813-709-8299
    Contact: Principal Investigator (Ana Suarez)
  • Neuroscience Research Institute - West Palm Beach, West Palm Beach, Florida, United States

    Contact: Principal Investigator (Danesh Alam)
  • Re:Cognition Health - Chicago, Chicago, Illinois, United States

    Contact: Principal Investigator (Abid Nazeer)
  • Indiana University Health Neuroscience Center, Indianapolis, Indiana, United States

    Contact: Principal Investigator (Michael Bushey)
  • University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States

    Contact: Principal Investigator (Shanna Babalonis)
  • Maryland Treatment Centers - Mountain Manor Treatment Center, Baltimore, Maryland, United States

    Contact: Principal Investigator (Marc Fishman)
  • Maryland Treatment Centers - Avery Road Treatment Center, Rockville, Maryland, United States

    Contact: Principal Investigator (Marc Fishman)
  • Brigham and Women's Hospital, Boston, Massachusetts, United States

    Contact: Principal Investigator (Joji Suzuki)
  • Adams Clinical Boston, Boston, Massachusetts, United States

    Contact: Principal Investigator (Darin Dougherty)
  • Boston Medical Center, Boston, Massachusetts, United States

    Contact: Principal Investigator (Alyssa Peterkin)
  • Adams Clinical Watertown, Watertown, Massachusetts, United States

    Study coordinator · 617-744-8542
    Contact: Principal Investigator (Daniel Rutrick)
  • SKY Integrative Medical Center/SKYCRNG, Ridgeland, Mississippi, United States

    Study coordinator · 601-567-1321
    Contact: Principal Investigator (Bob Hutchins)
  • Adams Clinical Harlem, New York, New York, United States

    Study coordinator · 917-423-67697
    Contact: Principal Investigator (Rachel Noone)
  • Adams Clinical Bronx, The Bronx, New York, United States

    Contact: Principal Investigator (Shama Farooq)
  • Ohio Clinical Trials, Columbus, Ohio, United States

    Study coordinator · 380-210-2424
    Contact: Principal Investigator (Angela Eakin)
  • Rivus Wellness and Research Institute, Oklahoma City, Oklahoma, United States

    Study coordinator · 405-753-4994
    Contact: Principal Investigator (Marvin Peyton)
  • Adams Clinical Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Principal Investigator (Cassie Blanchard)
  • Penn Medicine: University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States

    Study coordinator · 610-639-3592
    Contact: Principal Investigator (Kyle Kampman)
  • Brown University School of Public Health, Providence, Rhode Island, United States

    Contact: Principal Investigator (Carolina Haass-Koffler)
  • Avera Research Institute - Sioux Falls, Sioux Falls, South Dakota, United States

    Study coordinator · 605-504-3154
    Contact: Principal Investigator (Vivek Anand)
  • Adams Clinical Dallas, DeSoto, Texas, United States

    Contact: Principal Investigator (Benji Kurian)
  • Biopharma Informatic, LLC, Houston, Texas, United States

    Study coordinator · 281-944-3610
    Contact: Principal Investigator (James Lai, MD)
  • University of Virginia Health System, Charlottesville, Virginia, United States

    Study coordinator · 434-243-0563
    Contact: Principal Investigator (Nassima Ait-Daoud Tiouririne)
  • Carilion Clinic, Roanoke, Virginia, United States

    Study coordinator · 540-981-8025
    Contact: Principal Investigator (Albert Arias)
  • University of Washington - Harborview Medical Center, Seattle, Washington, United States

    Contact: Principal Investigator (Elenore Bhatraju)
  • CaRe Clinic, Calgary, Canada

    Study coordinator · 587-955-3401
    Contact: Principal Investigator (Sumantra Ghosh)
  • Med Trust Research, Courtice, Canada

    Study coordinator · 905-728-7915
    Contact: Principal Investigator (Hamilton Jeyaraj)
  • The Medical Arts Health Research Group, Kamloops, Canada

    Contact: Principal Investigator (Dustin Janz)
  • Kelowna Health and Memory Centre, Kelowna, Canada

    Contact: Principal Investigator (Eugene Okorie)
  • Providence Care, Kingston, Canada

    Study coordinator · 6135444900
    Contact: Principal Investigator (Roumen Milev)
  • Malton Medical Group, Mississauga, Canada

    Study coordinator · 905-677-4200
    Contact: Principal Investigator (Brian Zidel)
  • Comprehensive Treatment Clinic, Toronto, Canada

    Contact: Principal Investigator (Leonard Bienenstock)
  • Centre for Addiction and Mental Health (CAMH), Toronto, Canada

    Contact: Principal Investigator (Bernard Le Foll)
  • Research Works San Juan, Guaynabo, Puerto Rico

    Study coordinator · 787-315-1669
    Contact: Principal Investigator (Jose Feliberti)
  • Surrey and Borders Partnership NHS Foundation Trust, Chertsey, United Kingdom

    Contact: Principal Investigator (CHRISTOS KOUIMTSIDIS)
  • St Pancras Clinical Research - Eastbourne, Eastbourne, United Kingdom

    Study coordinator · 020 3865 1142
    Contact: Principal Investigator (Graham Campbell)
  • Queen Elizabeth University Hospital, Glasgow, United Kingdom

    Study coordinator · (+44) 0141 232 7600
    Contact: Principal Investigator (Nagore Penades)
  • St Pancras Clinical Research, London, United Kingdom

    Study coordinator · 02038651142
    Contact: Principal Investigator (Ward Lawrence)
  • Bioluminux - London, London, United Kingdom

    Contact: Principal Investigator (Laxmi Patel)
  • Lambeth Drug and Alcohol Treatment Consortium, London, United Kingdom

    Contact: Principal Investigator (michael kelleher)
  • Greater Manchester Mental Health NHS Foundation Trust, Manchester, United Kingdom

    Contact: Principal Investigator (Stephen Kaar)
  • Bioluminux Clinical Research - Milton Keynes, Milton Keynes, United Kingdom

    Contact: Principal Investigator (Kayode Timothy)
  • Bioluminux - Southampton, Southampton, United Kingdom

    Contact: Principal Investigator (joshua asubiaro)
  • Old Bank House Hillingdon Drug & Alcohol, Uxbridge, United Kingdom

    Contact: Principal Investigator (Jeffrey Fehler)
  • Bioluminux - Wolverhampton, Wolverhampton, United Kingdom

    Contact: Principal Investigator (Joshua Olofinlade)
Study leads
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

    Study Director

    Eli Lilly and Company